Renal denervation a treatment for resistant hypertension: A French experience;La dénervation rénale un traitement pour l'hypertension artérielle résistante: Expérience française

Annales de Cardiologie et d'Angeiologie

Volumn 62, Issue 6, 2013, Pages 384-391

  Benamer, H ^a,b   Mylotte, D ^b   Garcia Alonso, C ^b   Unterseeh, T ^b,c   Garot, P ^b,c   Louvard, Y ^a,b,c   Lefevre, T ^b   Morice, M C ^b  

^a ICV GVM Roseraie Aubervilliers   (France)

^b INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

^c Institut Claude Gallien   (France)

Author keywords

Renal denervation; Resistant hypertension; Sympathic activity

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AMBULATORY MONITORING; ARTERY SPASM; ARTICLE; BLOOD PRESSURE MONITORING; CATHETER; CLINICAL ARTICLE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FRANCE; GLOMERULUS FILTRATION RATE; HOME MONITORING; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; KIDNEY DYSFUNCTION; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AGED; CATHETER ABLATION; COMPLICATION; FEMALE; FOLLOW UP; HYPERTENSION; INNERVATION; KIDNEY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL ARTERY; RISK FACTOR; SYMPATHECTOMY;

AGED; ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL ARTERY; RISK FACTORS; SYMPATHECTOMY; TREATMENT OUTCOME;

EID: 84888025491     PISSN: 00033928     EISSN: 17683181     Source Type: Journal    
DOI: 10.1016/j.ancard.2013.09.003     Document Type: Article

References (31)

1. Doumas M., Papademetriou V., Douma S., Faselis C., Tsioufis K., Gkaliagkousi E., et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens 2011, 2011:1-8.
2. Krum H., Schlaich M., Sobotka P., Scheffers I., Kroon A.A., de Leeuw P.W. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J 2011, 32(5):537-544.
3. Mann S.J. Drug therapy for resistant hypertension: simplifying the approach. J Clin Hypertens (Greenwich) 2011, 13(2):120-130.
4. Esler M. Heart and mind: psychogenic cardiovascular disease. J Hypertens 2009, 27(4):692-695.
5. Guyton A.C., Coleman T.G., Granger H.J. Circulation: overall regulation. Annu Rev Physiol 1972, 34:13-46.
6. Campese V.M., Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25(4Pt 2):878-882.
7. Ciccone C.D., Zambraski E.J. Effects of acute renal denervation on kidney function in deoxycorticosterone acetate-hypertensive swine. Hypertension 1986, 8(10):925-931.
8. Schlaich M.P., Sobotka P.A., Krum H., Lambert E., Esler M.D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361(9):932-934.
9. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2Trial): a randomised controlled trial. Lancet 2010, 376(9756):1903-1909.
10. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373(9671):1275-1281.
11. Pathak A., Girerd X., Azizi M., Benamer H., Halimi J.M., Lantelme P., et al. Expert consensus: renal denervation for the treatment of arterial hypertension. Arch Cardiovasc Dis 2012, 105(6-7):386-393.
12. Václavík J.S.R., Plachy M., Navrátil K., Plásek J., Jarkovsky J., Václavík T., et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011, 57(6):1069-1075.
13. Schmieder R.E.R.J., Grassi G., Kjeldsen S.E., Mancia G., Narkiewicz K., Parati G., et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012, 30(5):837-841.
14. Faselis C., Doumas M., Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011, 2011:236-239.
15. Daugherty S.L.P.J., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L., O'Connor P.J., et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012, 125(13):1635-1642.
16. Papademetriou V., Doumas M., Faselis C., Tsioufis C., Douma S., Gkaliagkousi E., et al. Carotid baroreceptor stimulation for the treatment of resistant hypertension. Int J Hypertens 2011, 2011:964394.
17. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311(13):819-823.
18. Smithwick R.H., Thompson J.E. Splanchnicectomy for essential hypertension; results in 1,266cases. J Am Med Assoc 1953, 152(16):1501-1504.
19. Ukena C.M.F., Kindermann I., Barth C., Lenski M., Kindermann M., Brandt M.C., et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol 2001, 58(11):1176-1182.
20. de Araújo Gonçalves P.T.R., Raposo L. Catheter-based renal denervation for resistant hypertension performed by radial access. J Invasive Cardiol 2013, 25(3):147-149.
21. Zuern C.S.R.K., Eick C., Stoleriu C., Bunk L., Barthel P., Balletshofer B., et al. Effects of renal sympathetic denervation on 24-hour blood pressure variability. Front Physiol 2012, 3:134.
22. Mahfoud F., Schlaich M., Kindermann I., Ukena C., Cremers B., Brandt M.C., et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011, 123(18):1940-1946.
23. Schlaich M.P., Grassi G., Lambert G.W., Straznicky N., Esler M.D., Dixon J., et al. European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens 2009, 27(2):207-211.
24. Huang W.C., Fang T.C., Cheng J.T. Renal denervation prevents and reverses hyperinsulinemia-induced hypertension in rats. Hypertension 1998, 32(2):249-254.
25. Huggett R.J., Scott E.M., Gilbey S.G., Stoker J.B., Mackintosh A.F., Mary D.A. Impact of type 2diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation 2003, 108(25):3097-3101.
26. Oliveira V.L., Irigoyen M.C., Moreira E.D., Strunz C., Krieger E.M. Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats. Hypertension 1992, 19(2Suppl.):II17-II21.
27. Witkowski A., Prejbisz A., Florczak E., Kadziela J., Sliwinski P., Bielen P., et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011, 58(4):559-565.
28. Schlaich M.P.H.D., Sobotka P., Krum H., Lambert G.W., Lambert E., Esler M.D. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol 2012, 3:10.
29. Thomopoulos C., Michalopoulou H., Kasiakogias A., Kefala A., Makris T. Resistant hypertension and obstructive sleep apnea: the sparring partners. Int J Hypertens 2011, 2011:947246.
30. Davies J.E.M.C., Petraco R., Barron A.J., Unsworth B., Mayet J., Hamady M., et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013, 162(3):189-192.
31. Turner M.J., van Schalkwyk J.M. Is it ethical to perform irreversible renal denervation before a trial of low sodium intake for treatment-resistant hypertension?. Hypertension 2011, 58(2):e9. [author reply e10].